The global drug market for migraine treatment is massive and is expected to be worth around SEK 83.7 billion a year within the next six years. Our patented treatment method, Kinetic Oscillation Stimulation, K.O.S, is currently the subject of an international clinical study which is expected to treat the last patients during the third quarter of 2021.The migraine treatment was CE-marked in May of 2021, over than a year earlier than our initial plan. The K.O.S treatment for chronic rhinitis is CE-marked since long and under introduction in selected European markets and the Kingdom of Saudi Arabia. Our shares are listed on the Nordic Growth Market – SME with the ticker: CMH.

K.O.S has few or no unexpected effects

During treatment, the patient may experience some discomfort in the nose, but aside from that, K.O.S. has no other negative side effects.

K.O.S replaces existing medication

K.O.S can in many cases replace the medication used to treat migraine today. This means that many migraine patients can avoid pills and/or injections.

K.O.S has a positive socioeconomic impact

K.O.S treatment is cost effective, resulting also in less sick leave and reduced productivity losses.

Investor relations 
Investor relations 
Investor relations 
 

Articles, equity research & interviews

For questions about Chordate's share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Contact us

The information is handled according to our  privacy policy.